38499-94-4

Basic information

• Product Name: Benzoic acid, 4-methyl-, 2-(dithiocarboxy)hydrazide, monopotassium salt
• CAS NO: 38499-94-4
• Molecular Formula: C9H10N2OS2.K
• Molecular Weight: 264.414
• Mol File: 38499-94-4.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-methyl-, 2-(dithiocarboxy)hydrazide, monopotassium salt(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-methyl-, 2-(dithiocarboxy)hydrazide, monopotassium salt(38499-94-4)
• EPA Substance Registry System: Benzoic acid, 4-methyl-, 2-(dithiocarboxy)hydrazide, monopotassium salt(38499-94-4)

Safety Data

• Hazardous Substances Data: 38499-94-4(Hazardous Substances Data)

Upstream product

• 99-75-2 4-methyl-benzoic acid methyl ester 
• 874-60-2 4-methyl-benzoyl chloride 
• 94-08-6 4-methylbenzoic acid ethyl ester 
• 75-15-0 carbon disulfide 
• 3619-22-5 p-toluic hydrazide 

Downstream Products

• 78874-77-8 C₁₅H₁₄N₄S 

Relevant articles and documents

Heterocyclic amplifiers of phleomycin. V. Thiadiazolylpyridines and related compounds; Preliminary antitumour results

-

New heparanase-inhibiting triazolo-thiadiazoles attenuate primary tumor growth and metastasis

Compelling evidence ties heparanase, an endoglycosidase that cleaves heparan sulfate side (HS) chains of proteoglycans, with all steps of tumor development, including tumor initiation, angiogenesis, growth, metastasis, and chemoresistance. Moreover, heparanase levels correlate with shorter postoperative survival of cancer patients, encouraging the development of heparanase inhibitors as anti-cancer drugs. Heparanase-inhibiting heparin/heparan sulfate-mimicking compounds and neutralizing antibodies are highly effective in animal models of cancer progression, yet none of the compounds reached the stage of approval for clinical use. The present study focused on newly synthesized triazolo–thiadiazoles, of which compound 4-iodo-2-(3-(p-tolyl)-[1,2,4]triazolo[3,4b][1,3,4]thiadiazol-6-yl)phenol (4-MMI) was identified as a potent inhibitor of heparanase enzymatic activity, cell invasion, experimental metastasis, and tumor growth in mouse models. To the best of our knowledge, this is the first report showing a marked decrease in primary tumor growth in mice treated with small molecules that inhibit heparanase enzymatic activity. This result encourages the optimization of 4-MMI for preclinical and clinical studies primarily in cancer but also other indications (i.e., colitis, pancreatitis, diabetic nephropathy, tissue fibrosis) involving heparanase, including viral infection and COVID-19.

Design, synthesis, biological activity, crystal structure and theoretical calculations of novel 1,2,4-triazole derivatives

Series of 1,2,4-triazole Schiff base (Ia-f) were designed and synthesized. Their in-vitro antifungal activity to pythium solani, gibberlla nicotiancola, fusarium oxysporium fs.p. niveum and gibberlla saubinetii were evaluated. The results showed compound If exhibited good activity with tested fungi, which indicated that 1,2,4-triazole scaffold with introduction of imidazole phenyl could keep the antifungal activity. In order to further research the compound If, the crystal structure was detected by X-ray diffraction. Meanwhile, the FT-IR, FT-Raman, natural bond orbital (NBO), HOMO-LUMO and MEP were calculated at B3LYP/6-311G+(d,p) level. All the results will be helpful for further drug design in 1,2,4-triazole analogues.